Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04210128 · ClinicalTrials.gov registry record
Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 3
- Enrollment target
NCT04210128: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04210128 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04210128 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to see if continuous glucose monitoring can identify how often people who have pre-diabetes or medical obesity or well-controlled diabetes experience very high glucose values while receiving chemotherapy for breast cancer or pancreatic.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-12-20 |
| Est. Completion | 2023-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04210128
The ClinicalTrials.gov registry entry for NCT04210128 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04210128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04210128 about?
NCT04210128 is a clinical study titled "Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment". The purpose of this study is to see if continuous glucose monitoring can identify how often people who have pre-diabetes or medical obesity or well-controlled diabetes experience very high glucose values while receiving chemotherapy for breast cancer or pancreatic.
What is the current status of trial NCT04210128?
This trial is currently completed. The enrollment target is 3 participants. The study started on 2019-12-20. Estimated completion is 2023-10-31.
Who is sponsoring clinical trial NCT04210128?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.